These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Re: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Walsh PC J Urol; 2012 Sep; 188(3):810. PubMed ID: 22883758 [No Abstract] [Full Text] [Related]
23. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. Wong WW; Buskirk SJ; Schild SE; Prussak KA; Davis BJ J Urol; 2006 Nov; 176(5):2020-4. PubMed ID: 17070243 [TBL] [Abstract][Full Text] [Related]
24. Words of wisdom. Re: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Saad F Eur Urol; 2012 Nov; 62(5):932-3. PubMed ID: 23036346 [No Abstract] [Full Text] [Related]
25. ACP Journal Club. Periodic PSA-based screening in men 55 to 69 years of age reduced prostate cancer mortality. Hoffman RM Ann Intern Med; 2012 Jul; 157(2):JC2-4. PubMed ID: 22801696 [No Abstract] [Full Text] [Related]
26. The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence. Ginzburg S; Albertsen PC Endocrinol Metab Clin North Am; 2011 Sep; 40(3):615-23, ix. PubMed ID: 21889724 [TBL] [Abstract][Full Text] [Related]
27. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. Akaza H; Hinotsu S; Usami M; Ogawa O; Kagawa S; Kitamura T; Tsukamoto T; Naito S; Hirao Y; Murai M; Yamanaka H; Namiki M J Urol; 2006 Dec; 176(6 Pt 2):S47-9. PubMed ID: 17084166 [TBL] [Abstract][Full Text] [Related]
28. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer. Haliloglu A; Baltaci S; Yaman O J Urol; 2007 Jan; 177(1):128-30. PubMed ID: 17162022 [TBL] [Abstract][Full Text] [Related]
29. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571 [TBL] [Abstract][Full Text] [Related]
30. ACP Journal Club. Radical prostatectomy reduced mortality and disease progression over the long term more than watchful waiting in early prostate cancer. Canfield SE Ann Intern Med; 2011 Jul; 155(2):JC1-2. PubMed ID: 21768568 [No Abstract] [Full Text] [Related]
31. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464 [TBL] [Abstract][Full Text] [Related]
32. Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial. Bolla M; Hannoun-Levi JM; Ferrero JM; Maingon P; Buffet-Miny J; Bougnoux A; Bauer J; Descotes JL; Fourneret P; Jover F; Colonna M Radiother Oncol; 2010 Nov; 97(2):312-7. PubMed ID: 20846737 [TBL] [Abstract][Full Text] [Related]
33. Complications of androgen deprivation therapy in prostate cancer. Schwandt A; Garcia JA Curr Opin Urol; 2009 May; 19(3):322-6. PubMed ID: 19318949 [TBL] [Abstract][Full Text] [Related]
35. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258 [TBL] [Abstract][Full Text] [Related]
36. ACP Journal Club. Annual screening for prostate cancer did not reduce mortality from prostate cancer. Canfield SE Ann Intern Med; 2009 Jun; 150(12):JC6-4, JC6-5. PubMed ID: 19528549 [No Abstract] [Full Text] [Related]
37. Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term. Wilcox C; Kautto A; Steigler A; Denham JW Oncology; 2012; 82(1):56-8. PubMed ID: 22310055 [TBL] [Abstract][Full Text] [Related]
39. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer. Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032 [TBL] [Abstract][Full Text] [Related]
40. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Nishiyama T; Hashimoto Y; Takahashi K Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]